FIGURE S2 related to Figure 2. Effect of VMH T3 on liver and BAT metabolism (A)
Histological images of coronal sections of the rat brains showing the localization of the cannulae in the ventromedial (VMH) and (B) arcuate (ARC) nuclei of the hypothalamus. (C) Immunoreactivity of IBA1 and (D) protein levels of inflammatory markers in the VMH from single or chronic injection in the VMH (n=6-7 rats/group). (E) Body weight change (left panel) and daily food intake (right panel) of rats and chronically treated in the VMH with vehicle or T3 (n=9 rats/group). (F) Protein levels of the AMPK pathway in liver (left panel) and BAT (right panel) of rats receiving T3 "missed" injections in "VMH neighboring areas" (n=7 rats/group). (G) Body weight (left panel), daily food intake (middle panel) and mass change (right panel) of rats treated in the ARC with vehicle or T3 (n=9 rats/group). (H) Protein levels of UCP1 in BAT and (I) the AMPK pathway in liver (left panel) and BAT (right panel) of rats treated in the ARC with vehicle or T3 (n=7 rats/group). (J) Protein levels the AMPK pathway in liver (left panel) and BAT (right panel) of rats treated in the VMH with adenovirus encoding GFP or a dominant negative mutant of thyroid hormone receptor (TR-DN) (n=7 rats/group). (K) Body weight change (left panels) and (L) daily food intake (right panels) of sham and vagotomized (VGX) rats treated in the VMH with vehicle or T3 (n=7-8 rats/group). (M) Protein levels of UCP1 in BAT of sham and VGX rats treated in the VMH with vehicle or T3 (n=7 rats/group). *P<0.05, **P<0.01, ***P<0.001 vs. vehicle VMH, vehicle ARC. GFP or sham vehicle VMH; ### P<0.001 vs. VGX Vehicle VMH. All data are expressed as mean±SEM. (D) mRNA levels of enzymes involved in metabolism of complex lipids and (E) protein levels of the UPR in the cortex of euthyroid and hyperthyroid rats (n=7-8 rats/group). *P<0.05, **P<0.01, ***P<0.001 vs. euthyroid. All data are expressed as mean±SEM.
FIGURE S6 related to Figure 6. Effect of hypothalamic ceramides pathway on the central actions of THs on liver and BAT metabolism (A)
Protein levels of the UPR in the mediobasal hypothalamus (MBH) in hyperthyroid rats ICV treated with a vehicle or C6 ceramide (n=8-9 rats/group).
(B) Body weight change (left panel) and daily food intake (right panel) of hyperthyroid rats ICV treated with C6 ceramide or C6-dihydroceramide (C6-DHC) (n=8-9 rats/group).
(C-E) Protein levels of the AMPK pathway in the BAT (C), UCP1 in the BAT (D) and the AMPK pathway in the liver (E) of hyperthyroid rats ICV treated with C6 ceramide or C6-dihydroceramide (C6-DHC) (n=7 rats/group). (F) Body weight change (left panel) and daily food intake (right panel) of hyperthyroid rats treated in the ventromedial nucleus of the hypothalamus (VMH) with adenoviruses encoding GFP or serine palmitoyltransferase, long chain subunit 1-2 (SPTLC1-2) (n=8-9 rats/group).
(G-J) Protein levels of SPTCL1-2 and the UPR in the hypothalamus (G), the AMPK pathway in the BAT (H), UCP1 in the BAT (I) and the AMPK pathway in the liver (J) of hyperthyroid rats treated in the VMH with adenoviruses encoding GFP or SPTLC1-2 (n=7 rats/group).
(K) Protein levels of the UPR in the VMH of hyperthyroid rats treated in the VMH with adenoviruses encoding GFP or a dominant negative mutant of glucose regulated protein 78 KDa (GRP78-DN) (n=7-14 rats/group). *P<0.05, **P<0.01, ***P<0.001 vs Hyperthyroid vehicle ICV, Hyperthyroid C6-DHC ICV and Hyperthyroid GFP. All data are expressed as mean±SEM. 
